Abstract 2820
Background
Fine-needle aspiration biopsy (FNAB) is the standard diagnostic method of thyroid nodules. However, a fraction of the cytology assessments generates indeterminate results. Our group developed a method based on the relative quantification of three transcripts to aid the diagnosis of thyroid lesions. In this study, we aimed to validate the performance and applicability of this diagnostic test in FNAB.
Methods
Seventy-five prospectively collected FNAB were evaluated for CLDN10, HMGA2 and LAMB3 gene expression (EIF2B1 as reference gene) by RT-qPCR, using the leftover cells inside the needles. A mathematical model previously established was applied and the scores were compared with the Bethesda categories and the final postoperative report.
Results
We demonstrated the feasibility of the molecular test, even with very small yields of RNA. The three genes tested showed higher expression in the conclusive malignant cases (15 Bethesda VI) in relation to the conclusive benign nodules (35 Bethesda II). The application of the diagnostic algorithm allowed the distinction of these samples with 93% sensitivity (14/15) and 100% specificity (35/35). Among the patient with indeterminate nodules (Bethesda III-V), the test was able to correctly discriminate malignant from benign nodules with 71% sensitivity (5/7 tumors) and 100% specificity (4/4 benign lesions). Fourteen indeterminate cases are being followed-up and were not submitted to surgery to date. Furthermore, we observed that larger tumors (>1 cm), presenting lymph node metastasis and extrathyroidal extension were associated with higher algorithm scores (total of 22 malignant cases).
Conclusions
A thyroid diagnostic method based on the analysis of only four genes by RT-qPCR (3 targets and 1 reference) revealed high accuracy and applicability even in very limited FNAB material, presenting also a potential prognostic role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract
2037 - Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch Colorectal Cancer Group.
Presenter: Johannes Kwakman
Session: Poster Display session 2
Resources:
Abstract
3053 - JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies.
Presenter: Keisuke Kazama
Session: Poster Display session 2
Resources:
Abstract
3183 - Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, Phase 2 study
Presenter: Akitaka Makiyama
Session: Poster Display session 2
Resources:
Abstract
3233 - Biweekly TAS-102 and Bevacizumab as a Third-Line Chemotherapy for metastatic colorectal cancer: A Phase II Multicenter Clinical Trial (TAS-CC4 study)
Presenter: Yoichiro Yoshida
Session: Poster Display session 2
Resources:
Abstract
5907 - Liquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer
Presenter: Pashtoon Kasi
Session: Poster Display session 2
Resources:
Abstract
1866 - Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Presenter: Emilie Moati
Session: Poster Display session 2
Resources:
Abstract
2312 - High Circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab
Presenter: Jakob Schou
Session: Poster Display session 2
Resources:
Abstract
5602 - Clinical relevance of circulating tumor (ct)DNA genotyping for first line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): a prospective multicentric study
Presenter: JOANA Vidal Barrull
Session: Poster Display session 2
Resources:
Abstract
3182 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer
Presenter: Beili Wang
Session: Poster Display session 2
Resources:
Abstract